Marvisi, Chiara
 Distribuzione geografica
Continente #
AS - Asia 2.351
NA - Nord America 2.272
EU - Europa 1.436
SA - Sud America 330
AF - Africa 43
OC - Oceania 12
Totale 6.444
Nazione #
US - Stati Uniti d'America 2.228
CN - Cina 879
SG - Singapore 766
IT - Italia 466
HK - Hong Kong 296
BR - Brasile 282
DE - Germania 208
GB - Regno Unito 204
VN - Vietnam 148
RU - Federazione Russa 117
SE - Svezia 99
KR - Corea 98
FI - Finlandia 97
NL - Olanda 44
FR - Francia 41
ID - Indonesia 38
IE - Irlanda 35
AT - Austria 29
IN - India 23
LT - Lituania 21
CA - Canada 20
MX - Messico 19
AR - Argentina 18
BD - Bangladesh 18
BG - Bulgaria 17
JP - Giappone 17
TR - Turchia 17
MA - Marocco 15
AU - Australia 11
UA - Ucraina 11
IQ - Iraq 10
ZA - Sudafrica 10
ES - Italia 8
PL - Polonia 8
CL - Cile 7
IL - Israele 6
PT - Portogallo 6
UZ - Uzbekistan 6
AZ - Azerbaigian 5
CO - Colombia 5
CZ - Repubblica Ceca 5
EC - Ecuador 5
KE - Kenya 5
PE - Perù 5
PK - Pakistan 5
SA - Arabia Saudita 5
AE - Emirati Arabi Uniti 4
DZ - Algeria 4
GR - Grecia 4
BE - Belgio 3
VE - Venezuela 3
AL - Albania 2
CH - Svizzera 2
EG - Egitto 2
GY - Guiana 2
KG - Kirghizistan 2
LB - Libano 2
LV - Lettonia 2
PY - Paraguay 2
RS - Serbia 2
TH - Thailandia 2
TN - Tunisia 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BJ - Benin 1
BY - Bielorussia 1
BZ - Belize 1
IM - Isola di Man 1
KY - Cayman, isole 1
LI - Liechtenstein 1
MU - Mauritius 1
MW - Malawi 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PH - Filippine 1
RO - Romania 1
SN - Senegal 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
TW - Taiwan 1
UY - Uruguay 1
Totale 6.444
Città #
Santa Clara 660
Hefei 501
Singapore 497
Hong Kong 294
Ashburn 247
London 132
Munich 128
Chandler 101
Seoul 96
Beijing 86
Fairfield 81
Helsinki 76
Los Angeles 65
Nyköping 64
Milan 58
Dallas 54
Ho Chi Minh City 51
Moscow 49
The Dalles 48
Chicago 47
New York 42
Dublin 35
Hanoi 35
Jakarta 32
Seattle 30
Bologna 29
Kent 28
Buffalo 27
Houston 27
Cambridge 26
Shanghai 26
São Paulo 26
Nuremberg 25
Wilmington 24
San Diego 23
Woodbridge 23
Rome 22
Salt Lake City 19
Lauterbourg 18
Portsmouth 17
Redondo Beach 17
Princeton 15
Atlanta 14
Council Bluffs 14
Frankfurt am Main 14
Rio de Janeiro 14
Bremen 13
Haiphong 13
Modena 13
Amsterdam 12
Florence 12
Tampa 12
Vienna 12
Sofia 11
Boardman 10
Brooklyn 10
Elk Grove Village 10
Reggio Emilia 10
Tokyo 10
Ankara 9
Denver 9
Lappeenranta 9
Melbourne 9
Turku 9
Ann Arbor 8
Des Moines 8
Orem 8
Padova 8
Warsaw 8
Casablanca 7
Columbus 7
Lancaster 7
Manchester 7
Mexico City 7
San Francisco 7
Boston 6
Brasília 6
Brescia 6
Campinas 6
Curitiba 6
Dearborn 6
Düsseldorf 6
Montreal 6
Naples 6
Parma 6
Santiago 6
Stockholm 6
Tashkent 6
Thái Bình 6
Trieste 6
Verona 6
Baku 5
Caivano 5
Cremona 5
Dulles 5
Falls Church 5
Guangzhou 5
Hillsboro 5
Nairobi 5
Palermo 5
Totale 4.373
Nome #
Ultrasound Examination of Common Carotid Adventitial Thickness Can Differentiate Takayasu Arteritis and Large Vessel Giant Cell Arteritis 265
VEXAS Syndrome: A Case Series From a Single-Center Cohort of Italian Patients With Vasculitis 254
EULAR guidelines on ANCA-associated vasculitis in the real life 230
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study 171
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status 167
Chronic periaortitis presenting with isolated pulmonary artery involvement: description of two cases 162
New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group 158
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients 156
Management of Systemic Sclerosis Patients in the COVID-19 Era: The Experience of an Expert Specialist Reference Center 153
EVALUATION OF INTERNAL CONSISTENCY, FEASIBILITY, AND RELIABILITY OF THE ITALIAN VERSION OF ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME (AAV-PRO_ITA) QUESTIONNAIRE: PRELIMINARY RESULTS FROM A MULTICENTER STUDY ON A LARGE COHORT OF ITALIAN PATIENTS 144
Effectiveness and safety of a 26-week taper regimen of glucocorticoid in GCA patients: Results from a prospective cohort study 143
Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet’s Uveitis: Customizing Therapy according to the Clinical Features 139
Identification of two autoantigens recognised by circulating autoantibodies as potential biomarkers for diagnosing giant cell arteritis 131
Vessel inflammation and morphological changes in patients with large vessel vasculitis: A retrospective study 130
The management of large vessel vasculitides 127
Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study 126
Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study 125
Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases 124
117. PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG– STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS 122
EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS 118
354. EFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS 117
Prevalence and distribution of vascular calcifications at CT scan in patients with and without large vessel vasculitis: A matched cross-sectional study 115
Effects in soluble immune checkpoints induced by Tocilizumab monotherapy after ultra-short-term glucocorticoids in large vessel – giant cell arteritis patients 115
Development of the Takayasu Arteritis Integrated Disease Activity Index 111
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: results from the extension of the TOPAZIO study 110
C-reactive protein gene polymorphisms influence susceptibility and outcomes of biopsy-proven giant cell arteritis in Italian patients 110
Clinical and Prognostic Significance of Serum IgG4 in Chronic Periaortitis. An Analysis of 113 Patients 106
Elevated NET, Calprotectin, and Neopterin Levels Discriminate between Disease Activity in COVID-19, as Evidenced by Need for Hospitalization among Patients in Northern Italy 105
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) 105
What to Know About Biopsy Sampling and Pathology in Vasculitis? 102
Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss) 102
The role of PET/CT in disease activity assessment in patients with large vessel vasculitis 101
A large-scale genetic analysis reveals an autoimmune origin of idiopathic retroperitoneal fibrosis 100
Eosinophilic giant cell arteritis: A different subset of disease? 99
Trattamento con Tocilizumab in monoterapia dopo trattamento con glucocorticoidi per breve periodo in pazienti con arterite a cellule giganti con coinvolgimento dei grandi vasi: effetti sui checkpoint immunitari solubili 97
Pros and cons of TNF inhibitors and tocilizumab in the treatment of large-vessel vasculitis 97
The Role of PET in the Diagnosis and Disease Activity Assessment in Large Vessel Vasculitis 97
Validation of the Italian version of the ANCA-associated vasculitis patient-reported outcome (AAV-PRO) questionnaire 94
The role of sacro-iliac joint magnetic resonance imaging in the diagnosis of axial spondyloarthritis: focus on differential diagnosis in women 94
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis 94
Steroid-sparing agents in polymyalgia rheumatica: how will they fit into the treatment paradigm? 93
Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study 92
Senescent cells in giant cell arteritis display an inflammatory phenotype participating in tissue injury via IL-6-dependent pathways 92
Vasculitis, fibromuscular dysplasia or hereditary aneurysms? 88
Aortitis and periaortitis: The puzzling spectrum of inflammatory aortic diseases 86
Comment on: Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study. Reply 84
Reply 83
Takayasu arteritis and large-vessel giant cell arteritis in Italian population. Comprehensive analysis from a single institutional cohort of 184 cases 83
Comparing treatment options for large vessel vasculitis 82
Reply to Comment on: Vasculitis, fibromuscular dysplasia or hereditary aneurysms? by Marvisi et al 75
Systemic vasculitis: one year in review 2024 75
PREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURG-STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS 71
Idiopathic retroperitoneal fibrosis and its overlap with IgG4-related disease 70
Manifestations of Skull Base IgG4‐Related Disease: A Multi‐Institutional Study 64
The geographic and clinical clusters of Behçet’s syndrome 58
Hypereosinophilia and eosinophilic arterial aneurysm: not only eosinophilic granulomatosis with polyangiitis 53
Glucocorticoids versus glucocorticoids plus cyclophosphamide in eosinophilic granulomatosis with polyangiitis with poor-prognosis factors 47
Totale 6.512
Categoria #
all - tutte 30.513
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.513


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202154 0 0 0 0 0 6 9 3 8 5 7 16
2021/2022258 12 24 19 8 11 23 10 13 23 19 46 50
2022/2023483 35 47 28 20 69 51 33 52 60 22 38 28
2023/2024499 14 28 13 62 47 59 65 54 17 33 55 52
2024/20252.752 45 22 89 170 518 449 281 89 327 146 334 282
2025/20262.371 415 260 444 523 543 186 0 0 0 0 0 0
Totale 6.512